Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $2.2 million.

  • 60 Degrees Pharmaceuticals' Total Current Liabilities rose 6772.07% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 6772.07%. This contributed to the annual value of $1.7 million for FY2024, which is 4155.3% down from last year.
  • 60 Degrees Pharmaceuticals' Total Current Liabilities amounted to $2.2 million in Q3 2025, which was up 6772.07% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Total Current Liabilities peaked at $28.9 million during Q2 2023, and registered a low of $1.1 million during Q1 2024.
  • Its 4-year average for Total Current Liabilities is $6.3 million, with a median of $1.8 million in 2025.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 9577.59% in 2024, then skyrocketed by 6772.07% in 2025.
  • 60 Degrees Pharmaceuticals' Total Current Liabilities (Quarter) stood at $23.9 million in 2022, then tumbled by 88.15% to $2.8 million in 2023, then crashed by 41.55% to $1.7 million in 2024, then skyrocketed by 32.6% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $1.7 million for Q2 2025, and $1.8 million during Q1 2025.